Skip to main content
    P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.14
    -0.20 (-2.72%)

    Market Cap: $379.47M

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Puma Biotechnology Inc (PBYI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Puma Biotechnology (PBYI) has a market cap of $379.47M and an enterprise value of $337.92M. Its trailing P/E of 14.6x is above its 5-year median of 9.9x. It holds $41.55M more cash than debt, 10.95% of its market cap.

    Total Valuation

    Enterprise value is 10.95% below the market cap, as cash exceeds debt.

    Market Cap$379.47M
    Enterprise Value$337.92M
    Latest price (Nov 17, 2026)$7.14

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.30% in the quarter ended Sep 30, 2026 and grew 2.61% a year over 2 years.

    Shares Outstanding51.60M
    Shares Change (YoY)+2.51%
    Shares Change (QoQ)+1.30%
    Share Count Growth (2Y CAGR)+2.61%

    Valuation Ratios

    Sales and book value multiples are 1.6x and 2.5x. Its year-end P/E ranged from 3.9x to 21.1x from 2022 to 2025.

    P/E Ratio14.6x
    Forward P/E24.1x
    P/S Ratio1.6x
    P/B Ratio2.5x
    P/TBV Ratio3.3x
    P/OCF Ratio8.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 8.9x EBITDA.

    EV / Earnings14.2x
    EV / Sales1.5x
    EV / EBITDA8.9x

    Price Statistics

    The stock is up 46.01% over 52 weeks and trades 26.09% below its 50-day average.

    Beta (1Y)0.99
    52-Week Change+46.01%
    1-Month Change-30.07%
    3-Month Change-24.76%
    6-Month Change+4.85%
    5-Year Change+104.71%
    10-Year Change-72.74%
    Total Return (1Y)+46.01%
    Total Return (3Y CAGR)+22.85%
    Total Return (5Y CAGR)+16.21%
    Return vs SPY (1Y)+29.55%
    Max Drawdown (1Y)-36.59%
    Max Drawdown (3Y)-69.59%
    Sharpe Ratio (1Y)0.63
    Correlation with SPY (1Y)0.25
    50-Day Average$9.66
    200-Day Average$8.04
    52-Week Range$4.79 to $11.50
    RSI (14 Days)24.1
    Average Volume (20 Days)485.33K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.03x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.03x
    Quick Ratio2.81x
    Debt / Equity0.00x
    Interest Coverage5.79x

    Returns and Efficiency

    Return on equity is 16.25% and return on assets is 11.75% over the last 12 months.

    Return on Equity (ROE)16.25%
    Return on Assets (ROA)11.75%
    ROA (5Y Average)5.02%
    ROIC (5Y Average)17.16%
    Asset Turnover1.14x
    Inventory Turnover4.93x
    Receivables Turnover6.93x
    Cash Conversion Cycle102 days

    Taxes

    Income tax took 15.19% of pretax income over the last 12 months.

    Income Tax (TTM)$4.27M
    Effective Tax Rate15.19%

    Scores

    PBYI has an Altman Z-Score of -2.66, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-2.66
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $231.82M over the last 12 months is up 9.35% from the 12 months before.

    Revenue$231.82M
    Revenue Growth (YoY)+9.35%
    Gross Profit$170.60M
    Operating Income$26.14M
    Pretax Income$28.10M
    Net Income$23.83M
    EBITDA$36.65M
    Reported EPS (TTM)$0.49

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 72.30% of the $202.77M in total assets.

    Cash and Equivalents$41.55M
    Total Debt$0
    Net Cash$41.55M
    Net Cash Per Share$0.81
    Working Capital$105.66M
    Shareholder Equity$146.61M
    Book Value Per Share$2.84
    Tangible Book Value$112.53M
    Tangible Book Per Share$2.18
    Total Assets$202.77M
    Total Liabilities$56.15M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$46.04M
    FCF Per Share$0.89
    Depreciation and Amortization$10.21M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 11.27%, against a 5-year average of 10.91%.

    Gross Margin73.59%
    Operating Margin11.27%
    Pretax Margin12.12%
    Net Margin10.28%
    EBITDA Margin15.81%
    Gross Margin (5Y Average)74.13%
    Operating Margin (5Y Average)10.91%
    Net Margin (5Y Average)4.88%

    Growth

    Revenue grew 0.05% a year over 3 years, and EPS 48.12% a year.

    Revenue Growth (3Y CAGR)+0.05%
    Revenue Growth (5Y CAGR)+0.29%
    EPS Growth (3Y CAGR)+48.12%
    FCF Growth (5Y CAGR)+124.79%
    Operating Income Growth (3Y CAGR)+16.29%
    Book Value Per Share Growth (2Y CAGR)+50.80%

    Revenue and profit by year

    Dividends and Yields

    PBYI does not pay a dividend.

    Earnings Yield6.85%
    Buyback Yield-0.04%
    Shareholder Yield-0.04%

    Peer Position

    Against 7 similar companies, PBYI has the lowest P/S.

    P/S Ratio1.6x vs 7.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)+9.35% vs +54.02% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put EPS growth at -26.62% a year over the next 2 fiscal years.

    EPS Growth Forecast (2Y CAGR)-26.62%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PBYI

    What is PBYI's market cap?

    Puma Biotechnology has a market cap of $379.47M. Its enterprise value, which adds debt and subtracts cash, is $337.92M.

    What is PBYI's P/E ratio?

    Puma Biotechnology has a trailing P/E ratio of 14.6x and a forward P/E of 24.1x.

    How many shares of PBYI are outstanding?

    Puma Biotechnology has 51.60M shares outstanding. The count is up 2.51% from a year earlier.

    Does PBYI pay a dividend?

    No. Puma Biotechnology does not pay a dividend.

    How much debt does PBYI have?

    Puma Biotechnology has $0 of total debt and $41.55M of cash and equivalents, a net cash position of $41.55M.